Axe Compute Inc. (AGPU)

Axe Compute pivoted from oncology research into enterprise GPU infrastructure, securing a $260M multi-year contract to deploy NVIDIA’s latest accelerators. The company, which rebranded from Predictive Oncology in late 2025, now operates dual business segments: one supplying dedicated GPU clusters for large-scale AI workloads, the other continuing legacy drug discovery services. This shift reflects the broader market realignment toward infrastructure-heavy AI deployment, where raw compute capacity commands premium contracts from corporations scaling their machine learning operations.

The Infrastructure Play

Axe Compute’s core growth engine is compute services. In April 2026, the company inked a three-year enterprise contract valued at approximately $260 million to deliver a dedicated cluster of 2,304 NVIDIA B300 graphics processors. This arrangement locks in predictable revenue and establishes Axe as a mid-tier player in the booming AI infrastructure space—positioned above boutique consultancies but below hyperscaler behemoths like AWS and Google Cloud. The company manages the deployment, configuration, and ongoing support of these GPUs, absorbing both the capital cost and operational risk of maintaining specialized hardware for clients who need guaranteed capacity without owning the equipment outright.

Drug Discovery in the Background

The legacy business, Drug Discovery Services, still contributes to the balance sheet but has faded to secondary importance. Originally built on AI-driven predictive oncology—matching patient tumors to therapeutic candidates—this segment remains operational though revenue-light. The 2026 pivot suggests management recognized that pure software-as-a-service drug discovery cannot compete with in-house development at major pharmas; instead, licensing compute power to enterprises running their own AI models proved a more defensible business model with faster cash conversion.

At a Glance

Headquarters: Pittsburgh, Pennsylvania
Rebranding: Formerly Predictive Oncology; renamed December 2025
Primary Revenue: Enterprise GPU infrastructure contracts
Largest Contract: 36-month deal, ~$260M, 2,304 NVIDIA B300 GPUs
Market Cap: Approximately $27.5M (as of recent data)
Business Model: Dedicated compute leasing + legacy drug discovery services